New in Cephalalgia!
The evidence cited in the letter supports giving UdH greater attention in future population studies and burden estimates. At the same time, its clinical course and the benefits of any specific intervention require further study.
The authors therefore regard UdH as an important research and public health consideration, without assuming that every child with brief or mild
headache requires treatment.
https://t.co/4PkxjDKtSX
#migraine #headache #brain #pain #neurology #neuroscience
@deryauluduz
New in Cephalalgia!
Some other headache was unaccounted for in these studies; moreover, it was common: the Turkish study, with 7,088 participants, estimated its 1-year prevalence as 29.2%.6 The study authors labelled it “undifferentiated headache” (UdH) (in terminological alignment with A3.6 Undifferentiated
trigeminal autonomic cephalalgia in ICHD-3).
https://t.co/zty9LJXhlq
#migraine #headache #brain #pain #neurology #neuroscience
New in Cephalalgia!
The authors encourage colleagues within the international orofacial pain
and oral medicine communities, to evaluate our proposed criteria through independent validation studies and multicenter collaborative research.
https://t.co/L1jPkobkFP
#migraine #headache #brain #pain #neurology #neuroscience
New in Cephalalgia!
This Letter discusses how discordant negative-control outcomes should be interpreted when assessing residual bias in the cerebrovascular safety evaluation of CGRP monoclonal antibodies.
https://t.co/1JHsRzbjnA
#migraine#headache#brain#pain#neurology #neuroscience
New in Cephalalgia!
Both negative-control findings should inform interpretation, without treating the fracture result as confirmation of exchangeability or
the UTI result as a quantitative measure of bias in the primary outcome.
https://t.co/GA5m2HtqSW
#migraine#headache#brain #pain #neurology #neuroscience
@BradleyOngMD
~4 million Australians live with migraine.
Yet our new paper found just ONE NHMRC/MRFF-funded headache clinical trial from 2013–2025, and NONE for migraine or tension-type headache.
We need stronger investment and research capacity.
Cephalalgia is excited to announce the Jes Olesen Awards winners at the European Headache Congress!
Stay tuned to discover the winning papers: https://t.co/D36ljVLs5l
@JCephalalgia@ihs_official
New in Cephalalgia Reports!
Headache disorders are a leading cause of disability, yet publicly funded headache clinical trials in Australia are remarkably scarce. This new paper highlights the gap and the opportunity for change.
Article highlights
•
No funded clinical trials were identified for migraine or tension-type headache, despite their substantial burden.
•
A review of NHMRC and MRFF funding in Australia identified only one funded headache disorder clinical trial since 2013, focused on cluster headache.
•
Increased investment in headache clinical trials, workforce development, and national research infrastructure could help accelerate evidence generation and improve patient outcomes.
https://t.co/EdnwBt1ljj
#migraine #headache #brain #pain #neurology #neuroscience
@faradoost
📢 Call for Papers: Jes Olesen Awards for the Advancement of Headache Medicine 🧠🏆
Submissions are now open!
Cephalalgia invites researchers worldwide to submit their original research for the Jes Olesen Awards, recognising excellence and innovation in headache medicine.
🏆 Two prestigious awards:
🔬 Jes Olesen Basic Science Award
🩺 Jes Olesen Clinical Science Award
Each award includes:
💶 €10,000 prize
🌍 Recognition through Cephalalgia and IHS platforms
🎤 Opportunity to present at a major scientific meeting
✅ Eligibility:
• Original research papers only
• First author must be under 45 years of age at submission
• One submission per participant
📅 Submission deadline: 28 February 2027
📄 All submissions will undergo Cephalalgia's standard peer-review process, with winners selected from accepted papers by an expert panel.
The awards are generously funded by Professor Jes Olesen through JO Health to support and inspire the next generation of headache researchers.
🔗 Submit your research: https://t.co/DSZonTXcSc
More details: https://t.co/POKPSx9iyJ
Don't miss this opportunity to have your research recognised!
#JesOlesenAwards #Cephalalgia #IHS #HeadacheResearch #HeadacheMedicine #CallForPapers #headache
New in Cephalalgia Reports!
Can rheumatoid meningitis mask itself as a simple worsening of pre-existing migraine with aura? Yes, even without focal signs! Read how calculating the serum anti-CCP antibody (ACPA) index via the Reiber equation cracked this diagnostic puzzle.
https://t.co/heCQUpQXpV
#migraine #headache #brain #pain #neurology #neuroscience
New in Cephalalgia Reports!
A letter to the editor from Uzun and Sahin responding to the recent case series by Abdalla et al. on lamotrigine in migraine with aura.
https://t.co/KP9iQDlEQ1
#migraine#headache#brain#pain#neurology#neuroscience
New in Cephalalgia Reports!
A first-ever migraine aura was followed by a small cerebellar ischemic lesion in a patient with a patent foramen ovale, supporting a possible link between paradoxical microembolism, cortical spreading depression, and focal ischemia.
https://t.co/Z7L9FTsA9R
#migraine #headache #brain #pain #neurology #neuroscience
New in Cephalalgia Reports!
A 69-year-old man with chronic cluster headache enjoyed a notable reduction in attack frequency with memantine 20 mg twice daily. Off-label use of memantine in cluster headache should be considered in select patients.
https://t.co/SRM6OGGzia
#migraine #headache #brain #pain #neurology #neuroscience
New in Cephalalgia Reports!
In 1M+ headache-diary days, weather was a real but tiny correlate of headache reports — no reproducible "weather-sensitive" subgroup could be identified, no match to patients' own triggers, and near-chance day-level prediction.
https://t.co/ypCsjhRxr3
#migraine #headache #brain #pain #neurology #neuroscience
New in Cephalalgia Reports!
The first study in the world comparing pharmacopuncture, a type of acupuncture technique, to standard oral medication (propranolol) as prophylaxis treatment for migraine.
.............
GB20 pharmacopuncture with 2% lidocaine produced reductions in migraine frequency, disability and bothersome symptoms in the same direction as propranolol, without evidence of a statistically significant between-group difference.
•
GB20 pharmacopuncture with 2% lidocaine warrants further evaluation as a possible option for patients intolerant of or contraindicated for propranolol prophylaxis.
https://t.co/wSyj2nEdyB
#migraine #headache #brain #pain #neurology #neuroscience
New in Cephalalgia Reports!
This paper compared the ICHD-3 and DC/TMD diagnostic systems for headache attributed to temporomandibular disorder in the OPPERA-II cohort and found that the two approaches identify overlapping but clinically distinct headache presentations.
https://t.co/Snripomzgn
#migraine #headache #brain #pain #neurology #neuroscience
Excited to share a new Call for Papers in Cephalalgia — the official journal of the International Headache Society.
🧠 Special Issue: Managing and Understanding Headache in the Context of Comorbid Conditions
Guest Editors: Faraidoon Haghdoost and Henrik Winther Schytz
Headache disorders such as migraine and tension-type headache rarely exist in isolation. They often sit alongside high blood pressure, dyslipidaemia, depression, anxiety, gastrointestinal disorders, and more. This special issue focuses on integrated, real-world approaches to care — from shared pathophysiology and overlapping risk factors to multidisciplinary management and treatments that address both headache and comorbid conditions.
We welcome:
• Original research and clinical trials
• Systematic reviews and network meta-analyses
• Real-world evidence
• Viewpoints and perspectives
If your work explores headache in the context of comorbidities — cardiovascular, mental health, gastrointestinal, or beyond — we would love to hear from you.
📅 Submission deadline: 31 December 2026
📌 Please note in your cover letter that your manuscript is for the “Headache and Comorbidities” special issue.
Let’s move toward more holistic, patient-centred headache care. Looking forward to your submissions and to advancing this important conversation together.
https://t.co/xChfIATdM7
#migraine #headache #brain #pain #neurology #neuroscience
@faradoost@Simona_Sacco_@HenrikSchytz
New in Cephalalgia Reports!
Adjunctive masseter botox may improve outcomes in patients with chronic migraine and muscular temporomandibular disorder.
https://t.co/ViaJbu1tXF
#migraine#headache#brain#pain#neurology#neuroscience